This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Reiter A, Walz C, Watmore A, Schoch C, Blau I, Schlegelberger B et al. The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukaemia that fuses PCM1 to JAK2. Cancer Res 2005; 65: 2662–2667.
Murati A, Gelsi-Boyer V, Adelaide J, Perot C, Talmant P, Giraudier S et al. PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation. Leukemia 2005; 19: 1692–1696.
Bousquet M, Quelen C, De Mas V, Duchayne E, Roquefeuil B, Delsol G et al. The t(8;9)(p22;p24) translocation in atypical chronic myeloproliferative disorders yields a new PCM1-JAK2 fusion gene. Oncogene 2005; 24: 7248–7252.
Heiss S, Erdel M, Gunsilius E, Nachbaur D, Tzankov A . Myelodysplastic/myeloproliferative disease with erythropoietic hyperplasia (erythroid preleukemia) and the unique translocation (8;9)(p23;p24): first description of a case. Hum Pathol 2005; 36: 1148–1151.
Tefferi A, Gilliland DG . The JAK2 V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis. Mayo Clin Proc 2005; 80: 947–958.
Acknowledgements
This work has been supported by Institut Paoli-Calmettes, Inserm and grants from Laurette Fugain Association and from Ministries of Health and Research (Cancéropôle).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Adélaïde, J., Pérot, C., Gelsi-Boyer, V. et al. A t(8;9) translocation with PCM1-JAK2 fusion in a patient with T-cell lymphoma. Leukemia 20, 536–537 (2006). https://doi.org/10.1038/sj.leu.2404104
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404104
This article is cited by
-
TBL1XR1-JAK2: a novel fusion in a pediatric T cell acute lymphoblastic leukemia patient with increased absolute eosinophil count
Journal of Hematopathology (2020)
-
Genetic alterations of 9p24 in lymphomas and their impact for cancer (immuno-)therapy
Virchows Archiv (2019)
-
JAK/STAT signaling in hematological malignancies
Oncogene (2013)
-
Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1
Annals of Hematology (2013)
-
Targeted therapy in T-cell malignancies: dysregulation of the cellular signaling pathways
Leukemia (2010)